Long-acting insulin ‘probably superior’ to intermediate-acting insulin

Long-acting insulin is superior to intermediate-acting versions due to a greater reduction of haemoglobin A1c, new study finds

Several insulin formulations are available to treat hyperglycaemia in patients with type 1 diabetes. Andrea Tricco from St Michael’s Hospital, Toronto, and colleagues compared the relative effectiveness, safety and cost-effectiveness of long-acting insulin analogues (such as insulin glargine and insulin detemir) and intermediate-acting insulins (such as NPH insulin and insulin lente).

The meta-analysis of 39 studies suggests that long-acting insulin is “probably superior” owing to the greater reduction in haemoglobin A1c, less weight gain and lower incidence of severe hypoglycaemia compared with intermediate-acting insulin. Some, but not all, studies also found that long-acting insulin was more cost-effective than intermediate-acting insulin.

The choice of insulin should be tailored according to “preference, cost and accessibility”, say the researchers, writing in The
BMJ (online, 1 October 2014)[1]
.

References

 

[1] Tricco AC et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. The BMJ 2014. doi: 10.1136/bmj.g5459 (accessed 1 October 2014).

Last updated
Citation
The Pharmaceutical Journal, PJ, 11 October 2014, Vol 293, No 7831;293(7831):DOI:10.1211/PJ.2014.20066717